DOCSLIB.ORG

Li Wang Dartmouth Medical School

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Li Wang Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell B7.1/2 - CD28 Co-stimulatory: B7-H2 - ICOS MHC TCR B7 – CTLA-4 Co-inhibitory PD-L1/2 – PD-1 Checkpoint Pathways: B7-H3 – TLT2 B7-H4 – ? etc…….. Immune checkpoint-mediated T cell suppression during tumorigenesis Tumor PDL-1 PD-1 CTLA-4 B71/2 DC T effector CD28 -1 cells D PD-1 PDL-1 P -1 L D P Myeloid Suppressor CTLA-4 Foxp3+ cells Tregs Release the brake: Immune checkpoint blockade in cancer immunotherapy Antibody-mediated CTLA-4 blockade in combination with a cellular vaccine (Gvax) induced regression of established poorly immunogenic B16 melanoma. ● Elsas et.al. 1999, J Exp Med 190:355-366 Ipilimumab, the human aCTLA-4 mab, was approved by the FDA in March 2011 to treat patients with late-stage melanoma. Ipilimumab has also undergone early phase trials for other cancers, such as lung cancer and prostate cancer. ● Calabro et.al. 2010, Semin Oncol 37:460-467 Release the brake: Immune checkpoint blockade in tumor immunotherapy Blocking the PD-L1:PD-1 pathway, in conjunction with other immune therapies, inhibits tumor progression. ● Blank et.al. 2005, Cancer Immunol Immunother 54:307-314 ● Hirano et.al. 2005, Cancer Res 65:1089-1096 ● Geng et.al. 2006, Int J Cancer 118:2657-2664 ● Li et.al. 2009, Clin Cancer Res. 15: 1632-4 ● Pilon-Thomas et.al. 2010 J Immunol. 184: 3442-9 ● Weber J, 2010, Semin Oncol 37(5):430-9 MDX-1106, the human anti-PD-1 mab has entered clinical trials. ● Brahmer JR et.al. 2010, J Clin Oncol. 28(19):3167-75 Phase I study of anti-programmed death-1 (MDX-1106) as single-agent in refractory solid tumors is well tolerated and demonstrates clinical anti-tumor activity. The B7 Immunoglobulin Super-Family immune regulators APC T cell B7.1/2 - CD28 Co-stimulatory: B7-H2 - ICOS MHC TCR B7 – CTLA-4 Co-inhibitory PD-L1/2 – PD-1 Checkpoint Pathways: B7-H3 – TLT2 B7-H4 – ? VISTA VISTA: a new checkpoint protein, and a V-domain Immunoglobulin Suppressor of T cell Activation Ig-v domain TM cytoplasmic Ig-v domain structual model of VISTA, using PD-L1 as template Sequence of the Ig-v domain loop VISTA is highly expressed on CD11bhi myeloid cells Monocytes/macrophages DCs VISTA is expressed on T cells Peripheral LN Spleen 100 100 80 80 60 60 40 40 20 20 0 0 0 1 2 3 4 0 1 2 3 4 10 10 10 10 10 10 10 10 10 10 VISTA CD8+ cells CD4+ cells isotype + Foxp3 nTregs CD4+ naive CD4+ memory 100 100 100 80 80 80 60 60 60 40 40 40 20 20 20 0 0 0 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 VISTA VISTA expression on human PBMC cells CD11c+ CD8+ CD4+ Isotype CD11b+ Human VISTA Data contributed by Janet L. Lines Immobilized VISTA-Ig fusion protein inhibits T cell activation T cell proliferation Plate-bound CD3 + VISTA-Ig or control Ig CD3 : VISTA or control Ig 1:1 1:4 100 100 80 80 CD4+ 60 60 T cells 40 40 20 20 0 0 0 1 2 3 4 0 1 2 3 4 Control Ig 10 10 10 10 10 10 10 10 10 10 FL1-H: CFSE FL1-H: CFSE VISTA-Ig 100 100 80 80 + CD8 60 60 T cells 40 40 20 20 0 0 0 1 2 3 4 0 1 2 3 4 10 10 10 10 10 10 10 10 10 10 FL1-H: CFSE FL1-H: CFSE Immobilized VISTA-Ig fusion protein inhibits T cell activation Plate-bound CD3 + VISTA-Ig or control Ig ► Inhibit proliferation, but do not enhance apoptosis. ► Inhibit activation markers: CD69, CD44, CD62L. ► Inhibit T cell cytokine production (IL2, IFN etc). ► Suppression can be partially rescued by exogenous IL-2. ► PD-1 KO T cells are also inhibited. VISTA promotes the induction of adaptive Tregs Plate-bound CD3 + VISTA-Ig or control-Ig +/- TGF human mouse 30 40 % % + + 30 20 20 10 10 Foxp3GFP Foxp3GFP 0 0 VISTA-Ig - 2.5 5 ug/mL VISTA-Ig - - + TGF - -- TGF - + + VISTA expression on APC suppress T cell proliferation APC (A20 cells) + T cells (OTII) + peptide OVA peptide: 5 ng/mL 10 ng/mL A20-RFP A20-VISTA 100 100 70 80 80 60 60 60 50 40 40 40 30 20 20 20 0 0 CFSE-low% 100 101 102 103 104 100 101 102 103 104 10 CFSE 0 5 10 A20-VISTA A20-RFP OVA peptide (ng/ml) ● Similar results are obtained using BM-derived DCs that are transduced with VISTA-expressing retrovirus VISTA expression on tumors impairs protective tumor immunity Day-14 Day 0 Measure tumor growth (mm2) Irradiated Live tumor MCA105 Challenge: MCA105-RFP MCA105-VISTA MCA105-control MCA105-VISTA 125 ) 2 100 75 50 P = 0.0011 25 Tumor size (mm size Tumor 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (days) VISTA expression on tumors impairs protective tumor immunity Day-14 Day 0 Measure tumor growth (mm2) Irradiated Live tumor MCA105 Challenge: MCA105-RFP MCA105-VISTA 150 ) 2 T-depleted, ns 100 50 P= 0.0011 Tumor size (mm size Tumor 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 Time (days) MCA105-control MCA105-VISTA MCA105-control T-depletion MCA105-VISTA T-depletion VISTA monoclonal antibody treatment enhances inflammatory disease Day0 treat with control-Ig or VISTA SJL Monitor EAE progression Adoptive transfer primed pathogenic CD4+ T cells 3.0 (n=7) 13F3 100 control Ig(n=8) 90 2.5 p<0.0001 80 13F3 e r 2.0 70 control-Ig p<0.0001 60 1.5 50 40 1.0 Disease sco 30 20 0.5 Disease incidenceDisease (%) 10 0.0 0 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 7 9 11 13 15 17 19 21 23 25 27 29 31 33 Time (days) Time (days) VISTA-specific antibody controls tumor growth Bladder tumor IFN ELISPOT MB49 (s.c) 175 *** 150 125 100 75 50 25 spots/250k cells 0 control 13F3 VISTA-specific antibody controls tumor growth Fibrosarcoma Thymoma MCA105 (s.c) EG7 (s.c) VISTA-specific antibody controls tumor growth Ovarian tumor ID8-luciferase (peritoneal) Control-Ig 13F3 Day30 Day55 p value:0.03 p= 0.0167 ) ) 5 4 (n=8) 120 60 (n=8) 100 50 80 40 60 30 40 20 20 10 Total photon flux (X 10 (X flux photon Total Total photon flux (X 10 (X flux photon Total 0 0 control +13F3 control +13F3 VISTA-specific antibody controls tumor growth Skin tumor B16F10-OVA Vaccine: CD40 agonist + LPS + OVA control 13F3 control + vaccine 13F3+vaccine 175 ) 2 150 125 100 75 50 tumor size (mm 25 0 11 13 15 17 19 21 23 25 Days VISTA-specific antibody controls tumor growth B16F10 (day-2 prophylactic treatment) 175 150 125 100 *** control (n=10) 13F3 (n=18) 75 MIH5 50 tumor size (mm2) 25 0 6 8 10 12 14 16 18 20 22 Days Combinatorial blockade of VISTA and PD-L1/PD-1 results in better tumor control B16F10 (day+4 therapeutic treatment) ) 2 200 150 control (n=10) MIH5 (n=10) 100 *** 113F3 (n=16) combo (n=16) 50 tumor size (mm 0 6 8 10 12 14 16 18 20 Days VISTA and PD-L1/PD-1 synergize to suppress T cell proliferation VISTA-Ig fusion protein + PD-L1-Ig fusion protein + CD3/CD28 CD4+ T cells CD8+ T cells 100 100 75 75 50 50 25 25 CFSE-low cells% 0 CFSE-low cells% 0 -Ig -Ig bo -Ig -Ig bo NA m NA m VISTA PDL1 co VISTA PDL1 co The inducible melanoma model Tyr::Cre/ERT2: Tyrosinase promoter driven expression of Cre-ERT2, permitting tamoxifen-inducible, melanocyte-specific cre expression. BrafCA: carrying a conditional BrafV600E allele, permitting cre-mediated expression of BrafV600E Pten1ox5: carrying a conditional allele of Pten, permitting cre-mediated deletion of exon 5 Dankort et al 2009 Nature Immunology High VISTA expression within the tumor microenvironment gated CD11c+ CD11b+ 19.8 3.18 33 50.2 TIL naïve LN dLN isotype VISTA 6.59 40.6 38.7 7.85 CD11C CD11b VISTA VISTA blockade inhibited the growth of the inducible melanoma Conclusions VISTA functions as a novel immune checkpoint protein ligand: controls inflammation and autoimmunity. impairs the generation of anti-tumor immunity. VISTA antibody-mediated blockade either alone, or in combination with other checkpoint blockade might provide a novel therapeutic strategy for cancer immunotherapy. J Exp Med, 2011, 208(3):577-92 ACKNOWLEDGEMENTS Noelle Lab Almo Lab (Dartmouth Medical School, NH) (Albert Einstein College of Medicine) (King’s college in London, UK) Steve Almo Randy Noelle Rotem Rubinsteine Janet Louise Lines Cory Ahonen Andras Fiser Petra Sergent (Albert Einstein College of Medicine).
Load more

Recommended publications
  • TNF‑Α‑Mediated Epithelial‑To‑Mesenchymal Transition Regulates Expression of Immune Checkpoint Molecules in Hepatocellular Carcinoma
    MOLECULAR MEDICINE REPORTS 21: 1849-1860, 2020 TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma RITU SHRESTHA1,2, KIM R. BRIDLE1,2, DARRELL H.G. CRAWFORD1,2 and APARNA JAYACHANDRAN1,2 1University of Queensland, Faculty of Medicine and 2Liver Cancer Unit, Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia Received June 12, 2019; Accepted January 31, 2020 DOI: 10.3892/mmr.2020.10991 Abstract. Hepatocellular carcinoma (HCC) is the ligand (PD‑L)1, PD‑L2, CD73 and B7‑H3. In contrast, reversal fastest growing cause of cancer-related deaths globally. of EMT suppressed the expression of PD‑L1, PD‑L2, CD73 Epithelial-to-mesenchymal transition (EMT) is a cellular and B7‑H3. In addition, high expression of TNF-α and PD‑L1 process that confers HCC tumor cells with the ability to evade in 422 patients with HCC was associated with poor overall the immune system. Immune escape in most tumors, including survival. The coordinate expression of TNF-α with PD‑L2 in HCC, is controlled by immune checkpoint molecules. The aim this patient cohort was associated with increased HCC recur- of the present study was to investigate the association between rence. In conclusion, the present study demonstrated a close EMT and immune checkpoint in HCC, and identify novel ther- association between immune modulator expression and EMT apeutic targets for HCC. An in vitro model of reversible EMT induction/reversal driven by TNF-α. was utilized based on cytokine tumor necrosis factor (TNF)-α treatment of HCC cell lines Hep3B and PLC/PRF/5.
    [Show full text]
  • Superpixel Image Segmentation of VISTA Expression in Colorectal Cancer: Implications for Immunotherapy
    Superpixel Image Segmentation of VISTA Expression in Colorectal Cancer: Implications for Immunotherapy Dongling Wu Zucker School of Medicine at Hofstra Northwell Health Sean Hacking Zucker School of Medicine at Hofstra Northwell Health Taisia Vitkovski Zucker School of Medicine at Hofstra Northwell Health Mansoor Nasim ( [email protected] ) Zucker School of Medicine at Hofstra Northwell Health Research Article Keywords: Colorectal Carcinoma, v-domain immunoglobulin suppressor of T cell activation, VISTA, Immunohistochemistry, Superpixel, Clinical trials Posted Date: December 14th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-120759/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/24 Abstract Colorectal cancer is an overall bad player and accounts for 9% of all cancers. Today, advancements in immune checkpoint inhibition has provided therapeutics for many, but not all cancer patients. This issue is in part due to the tumoral microenvironment; which plays a signicant role in determining response to immune check point therapeutics. This study serves as the rst to evaluate a potent inhibitory checkpoint: V-domain immunoglobulin suppressor of T cell activation (VISTA) and its role in CRC. This was evaluated with both conventional light microscope and superpixel image segmentation. Here we found VISTA expression to be associated with low tumor budding, lower tumor stage, high tumor inltrating lymphocytes, mature stromal differentiation, BRAF mutation status and better disease-free survival in colorectal cancer. When comparing methodologies; superpixel image segmentation better stratied patients into prognostic groups. Anti-VISTA clinical trials are now open and recruiting for patient enrollment for patients with certain advanced solid tumors.
    [Show full text]
  • VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
    Cancer Immunology Cancer Immunology at the Crossroads: Experimental Immunotherapies Research VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy J. Louise Lines1,2, Lorenzo F. Sempere3, Thomas Broughton4,5, Li Wang7, and Randolph Noelle1,2,4,5,6 Abstract In the past few years, the field of cancer immunotherapy has made great progress and is finally starting to change the way cancer is treated. We are now learning that multiple negative checkpoint regulators (NCR) restrict the ability of T-cell responses to effectively attack tumors. Releasing these brakes through antibody blockade, first with anti-CTLA4 and now followed by anti-PD1 and anti-PDL1, has emerged as an exciting strategy for cancer treatment. More recently, a new NCR has surfaced called V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation (VISTA). This NCR is predominantly expressed on hematopoietic cells, and in multiple murine cancer models is found at particularly high levels on myeloid cells that infiltrated the tumors. Preclinical studies with VISTA blockade have shown promising improvement in antitumor T-cell responses, leading to impeded tumor growth and improved survival. Clinical trials support combined anti-PD1 and anti-CTLA4 as safe and effective against late-stage melanoma. In the future, treatment may involve combination therapy to target the multiple cell types and stages at which NCRs, including VISTA, act during adaptive immune responses. Cancer Immunol Res; 2(6); 510–7. Ó2014 AACR. Introduction Negative Checkpoint Regulators, New and Old The concept of immunosurveillance for cancer was pro- Molecules that promote or interfere with the mounting of posed by Burnet (1), who posited that transformed cells protective antitumor immunity are under intensive study.
    [Show full text]
  • Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
    King’s Research Portal DOI: 10.3389/fimmu.2019.00453 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J., French, E., Hoffmann, R. M., Williams, I. P., Cheung, K. K. A., Thair, B., Beales, C. T., Touizer, E., Signell, A. W., Tasnova, N. L., Spicer, J. F., Josephs, D. H., ... Karagiannis, S. N. (2019). Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology , (MAR), [453]. https://doi.org/10.3389/fimmu.2019.00453 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
    [Show full text]
  • Spatially Resolved and Quantitative Analysis of VISTA/PD-1H As a Novel Immunotherapy Target in Human Non–Small Cell Lung Cance
    Published OnlineFirst December 4, 2017; DOI: 10.1158/1078-0432.CCR-17-2542 Personalized Medicine and Imaging Clinical Cancer Research Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer Franz Villarroel-Espindola1, Xiaoqing Yu2, Ila Datar1, Nikita Mani1, Miguel Sanmamed3, Vamsidhar Velcheti4, Konstantinos Syrigos5, Maria Toki1, Hongyu Zhao2, Lieping Chen3, Roy S. Herbst6, and Kurt A. Schalper1,6 Abstract Purpose: Determine the localized expression pattern and clin- Expression in tumor and stromal cells was seen in 21% and ical significance of VISTA/PD-1H in human non–small cell lung 98% of cases, respectively. The levels of VISTA were positively þ þ cancer (NSCLC). associated with PD-L1, PD-1, CD8 TcellsandCD68 Experimental Design: Using multiplex quantitative immuno- macrophages. VISTA expression was higher in T-lymphocytes fluorescence (QIF), we performed localized measurements of than in macrophages; and in cytotoxic T cells than in T-helper VISTA, PD-1, and PD-L1 protein in 758 stage I–IV NSCLCs from cells. Elevated VISTA was associated with absence of EGFR 3 independent cohorts represented in tissue microarray format. mutations and lower mutational burden in lung adenocarci- þ The targets were selectively measured in cytokeratin tumor nomas. Presence of VISTA in tumor compartment predicted þ þ þ epithelial cells, CD3 T cells, CD4 T-helper cells, CD8 cytotoxic longer 5-year survival. þ þ T cells, CD20 B lymphocytes and CD68 tumor-associated Conclusions: VISTA is frequently expressed in human NSCLC macrophages. We determined the association between the targets, and shows association with increased tumor-infiltrating lympho- clinicopathological/molecular variables and survival.
    [Show full text]
  • Spatially Resolved and Quantitative Analysis of VISTA/PD-1H As a Novel
    Author Manuscript Published OnlineFirst on December 4, 2017; DOI: 10.1158/1078-0432.CCR-17-2542 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in 2 human non-small cell lung cancer 3 Franz Villarroel-Espindolaa, Xiaoqing Yub, Ila Datara, Nikita Mania, Miguel Sanmamedc, Vamsidhar 4 Velchetid, Konstantinos Syrigose, Maria Tokia, Hongyu Zhaob, Lieping Chenc, Roy S. Herbstf and Kurt A. 5 Schalpera,f 6 aDepartment of Pathology, Yale School of Medicine, New Haven, CT, 06520 USA. 7 bDepartment of Public Health, Yale School of Medicine, New Haven, CT, 06520 USA. 8 cImmunobiology, Yale School of Medicine, New Haven, CT, 06520 USA. 9 dSolid Tumor Oncology, Cleveland Clinic Foundation, Cleveland, OH, 44195 USA. 10 eOncology Unit GPP, Athens School of Medicine, Greece. 11 fMedical Oncology and Yale Cancer Center, New Haven, CT, 06520 USA. 12 Running title: Role of VISTA/PD-1H in NSCLC. 13 Keywords: NSCLC, VISTA/PD-1H, PD-1 pathway, TILs 14 Correspondence to: 15 Kurt A. Schalper, M.D./Ph.D. 16 Office Address: 333 Cedar St. FMP117, New Haven, CT 06520-8023 17 Email: [email protected] 18 Financial support: 19 Lung Cancer Research Foundation (LCRF), Yale SPORE in Lung Cancer (P50CA196530), Department of 20 Defense-Lung Cancer Research Program Career Development Award (LC150383), Stand Up to Cancer – 21 American Cancer Society Lung Cancer Dream Team Translational Research Grant (Grant Number: SU2C- 22 AACR-DT17-15). Stand Up To Cancer is a program of the Entertainment Industry Foundation.
    [Show full text]
  • Evaluating the Potential for B7-H4 As an Immunoregulatory Target
    Author Manuscript Published OnlineFirst on March 21, 2017; DOI: 10.1158/1078-0432.CCR-15-2440 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 2 Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target 3 Heather L. MacGregor1,2 and Pamela S. Ohashi1-3* 4 5 6 7 1Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, 8 Toronto, Ontario, Canada 9 2Department of Immunology, University of Toronto, Toronto, Ontario, Canada 10 3Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada 11 12 13 Running Title: Evaluating B7-H4 as a Potential Immunoregulatory Target 14 Keywords: B7-H4; immunosuppression; co-inhibitory molecule; immunotherapy; tumor 15 microenvironment 16 17 Funding sources: This work was supported by grants from the Canadian Institute for Health 18 Research awarded to P.S. Ohashi. 19 20 *Corresponding Author: Pamela S. Ohashi, Princess Margaret Cancer Centre, 610 University 21 Avenue, Suite 8-407, Toronto, Ontario M5G 2M9, Canada. Phone: 416-946-2357; Fax: 416-204- 22 2276; e-mail: [email protected] 23 Disclosures: The authors have no financial conflicts of interest. 1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 21, 2017; DOI: 10.1158/1078-0432.CCR-15-2440 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 24 (Abstract: 152 words; Body: 2937 words; 2 figures, 1 table) 25 Abstract: With the clinical success of CTLA-4 and PD-1 blockade in treating malignancies, 26 there is tremendous interest in finding new ways to augment anti-tumor responses by targeting 27 other inhibitory molecules.
    [Show full text]
  • Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma Hirokazu Sadahiro1,2, Kyung-Don Kang1, Justin T
    Published OnlineFirst March 12, 2018; DOI: 10.1158/0008-5472.CAN-17-2433 Cancer Tumor Biology and Immunology Research Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma Hirokazu Sadahiro1,2, Kyung-Don Kang1, Justin T. Gibson3, Mutsuko Minata1, Hai Yu1,4, Junfeng Shi5, Rishi Chhipa6, Zhihong Chen7, Songjian Lu8, Yannick Simoni9, Takuya Furuta10, Hemragul Sabit11, Suojun Zhang1,12, Soniya Bastola1, Shinobu Yamaguchi1, Hebaallah Alsheikh1, Svetlana Komarova1, Jun Wang1, Sung-Hak Kim13, Dolores Hambardzumyan7, Xinghua Lu8,EvanW.Newell9, Biplab DasGupta6, Mitsutoshi Nakada11, L. James Lee5, Burt Nabors1, Lyse A. Norian3,14, and Ichiro Nakano1,14 Abstract Glioblastoma (GBM) is a lethal disease with no effective ther- We also found that treatment of GSC-derived mouse GBM tumors apies available. We previously observed upregulation of the TAM with nivolumab, a blocking antibody against the immune check- (Tyro-3, Axl, and Mer) receptor tyrosine kinase family member AXL point protein PD-1, increased intratumoral macrophages/micro- in mesenchymal GBM and showed that knockdown of AXL glia and activation of AXL. Combinatorial therapy with nivolumab induced apoptosis of mesenchymal, but not proneural, glioma plus BGB324 effectively prolonged the survival of mice bearing sphere cultures (GSC). In this study, we report that BGB324, a GBM tumors. Clinically, expression of AXL or PROS1 was associ- novel small molecule inhibitor of AXL, prolongs the survival of ated with poor prognosis for patients with GBM. Our results immunocompromised mice bearing GSC-derived mesenchymal suggest that the PROS1–AXL pathway regulates intrinsic mesen- GBM-like tumors. We show that protein S (PROS1), a known chymal signaling and the extrinsic immune microenvironment, ligand of other TAM receptors, was secreted by tumor-associated contributing to the growth of aggressive GBM tumors.
    [Show full text]
  • Francis Collins' Notes on the Press Release
    '-\ \\ \ EMBARGOED UNTIL 10 am EST, February 12, 2001 International Human Genome Sequencing Consortium Publishes Sequence and Analysis of the Human Genome Washington, D.C., Feb. 12, 2'1-The Human Genome Project international consortium today it has ptlblished a draft sequence and initial analysis of the human genome-the genetic blueprint for a human being. The paper will be published in the Feb. 15 issue of the journal Nature. The draft sequence, which covers more than 90 percent of the human genome, represents the exact order of DNA's four chemical bases, commonly abbreviated A, T, C and G, arrayed along the human chromosomes. This text underlies and shapes ever man trait-from eye color and height, to health, diseases, an 7 The Consortium's initial analysis of this text describes some of the insights that can be gleaned from the genome and represents scientists' first glimpse r\JJ.. of the human DNA terrain- its quirks and curiosities, as well as the extraordinary trove of information about human development, physiology, medicine, and evolution. The results reported in Nature paper represents the next milestone since the , consortium's announcement on June 26 that it had a fiist ..assembly gf tho human goRome. Tlie fi:fst assembly aH:fl6tlnced in June -.vas ,analt:Jgotts to ha...-ing a eolleetit:Jn of all thQ letters that percent of "tl..t_ "i the text for the "Book of Life." This week's paper representra;c;ompilation of _u these . into .the first draft of a readable GoA '"•, 1> p • small gaps still remaining to be filled in this text, but 11'-CAN"'\ scientists are already getting of what the genome topography looks like it has to tell.
    [Show full text]
  • Changes in the Adipose Tissue Expression of CD86 Costimulatory
    Sindhu et al., J Glycomics Lipidomics 2015, 5:4 DOI: 10.4172/2153-0637.1000135 Journal of Glycomics & Lipidomics Research Article Open Access Changes in the Adipose Tissue Expression of CD86 Costimulatory Ligand and CD163 Scavenger Receptor in Obesity and Type-2 Diabetes: Implication for Metabolic Disease Sardar Sindhu1*, Reeby Thomas1, Shihab Kochumon1, Eman Alshawaf2, Amal Hasan1, Munera Alghanim1, Kazem Behbehanil2 and Rasheed Ahmad1* 1Immunology & Innovative Cell Therapy Unit, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait 2Pancreatic Islet Biology and Transplantation Unit, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait Abstract Background: The CD86 costimulatory ligand and CD163 scavenger receptor are expressed on monocytes/macrophages. However, modulations in the expression of these immune regulatory receptors in metabolic disease remain unclear. We, therefore, compared the adipose tissue expression of CD86/CD163 and signature inflammatory cytokines/chemokines in non-diabetic and diabetic individuals. Methods: Subcutaneous adipose tissue biopsies were collected from 57 non-diabetics and 46 diabetics classified based on body mass index as obese, overweight and lean and the expression of CD86/CD163 was assessed by quantitative RT-PCR, immunohistochemistry/ confocal microscopy. Results: The data show that CD86 and CD163 gene expression was elevated in non-diabetic obese individuals as compared with their lean counterparts (P [CD86] = 0.0035; P [CD163] = 0.0028). As expected, CD86 and CD163 protein expression was also found to be elevated in the adipose tissue samples of obese individuals. The CD86 gene expression in non-diabetic and diabetic individuals correlated positively (P<0.05) with that of TNF-α (r [non-diabetic] = 0.26; r [diabetic] = 0.49), IL-18 (r [non-diabetic] = 0.67; r [diabetic] = 0.63), and IL-8 (r [non-diabetic] = 0.38; r [diabetic] = 0.33).
    [Show full text]
  • VISTA Regulates the Development of Protective Antitumor Immunity
    Cancer Microenvironment and Immunology Research VISTA Regulates the Development of Protective Antitumor Immunity Isabelle Le Mercier1, Wenna Chen1, Janet L. Lines3,4, Maria Day2, Jiannan Li1, Petra Sergent1, Randolph J. Noelle1,3,4, and Li Wang1 Abstract V-domain Ig suppressor of T-cell activation (VISTA) is a novel negative checkpoint ligand that is homologous to PD-L1 and suppresses T-cell activation. This study demonstrates the multiple mechanisms whereby VISTA relieves negative regulation by hematopoietic cells and enhances protective antitumor immunity. VISTA is highly þ þ expressed on myeloid cells and Foxp3 CD4 regulatory cells, but not on tumor cells within the tumor microenvironment (TME). VISTA monoclonal antibody (mAb) treatment increased the number of tumor- specific T cells in the periphery and enhanced the infiltration, proliferation, and effector function of tumor- reactive T cells within the TME. VISTA blockade altered the suppressive feature of the TME by decreasing the presence of monocytic myeloid-derived suppressor cells and increasing the presence of activated dendritic cells within the tumor microenvironment. In addition, VISTA blockade impaired the suppressive function and reduced þ þ the emergence of tumor-specific Foxp3 CD4 regulatory T cells. Consequently, VISTA mAb administration as a monotherapy significantly suppressed the growth of both transplantable and inducible melanoma. Initial studies explored a combinatorial regimen using VISTA blockade and a peptide-based cancer vaccine with TLR agonists as adjuvants. VISTA blockade synergized with the vaccine to effectively impair the growth of established tumors. Our study therefore establishes a foundation for designing VISTA-targeted approaches either as a monotherapy or in combination with additional immune-targeted strategies for cancer immunotherapy.
    [Show full text]
  • High Expression of Immune Checkpoints Is Associated with the TIL Load, Mutation Rate and Patient Survival in Colorectal Cancer
    INTERNATIONAL JOURNAL OF ONCOLOGY 57: 237-248, 2020 High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer MARA KITSOU1, GEORGIOS D. AYIOMAMITIS2 and APOSTOLOS ZARAVINOS3 1Department of Life Sciences, School of Sciences, European University Cyprus, 1516 Nicosia, Cyprus; 2First Department of Surgery, Tzaneio General Hospital, 18536 Piraeus, Greece; 3College of Medicine, Member of QU Health, Qatar University, P.O. Box 2713 Doha, Qatar Received February 10, 2020; Accepted April 13, 2020 DOI: 10.3892/ijo.2020.5062 Abstract. Adoptive cell therapy with the use of tumor- ‘central memory T-cell’ and ‘exhausted T-cell’ gene signa- infiltrating lymphocytes (TILs) is a very promising tures were significantly lower among the READ tumors. The immunotherapeutic approach for the treatment of patients expression of PD‑1, PD‑L1, PD‑L2, CTLA‑4 and IDO1 was with colorectal cancer (CRC). However, within the tumor significantly higher among COAD patients with a high muta- microenvironment, co-inhibitory immune checkpoints can tion rate (>34 mutations/Mb) compared to those with a lower inactivate TILs. The aim of the present study was to examine rate. Somatic mutations in PD‑1, PD‑L1, CTLA‑4 and other the association between the TIL load, the mutation rate and checkpoint molecules did not seem to affect their expression the clinical outcome in the immune landscape of patients with levels. On the whole, the data of the present study highlight CRC. RNA-seq and whole exome seq data of 453 colon adeno- the association of immune checkpoint molecules with the TIL carcinomas (COAD) and rectal adenocarcinomas (READ), load, patient survival and a high mutation rate in CRC.
    [Show full text]